Company intelligence / Profile preview
Premas Biotech
Gurugram, Haryana, Indiapremasbiotech.com ↗
- Ownership
- Private
- Employees
- ~150
- Development stage
- Preclinical
01
Overview
Premas Biotech’s lead program is an oral, triple-antigen virus-like particle (VLP) COVID‑19 vaccine candidate ("PRAK‑03202"/Oravax), which has reported positive preliminary Phase 1 data. The company also has discovery-stage programs in RSV and influenza vaccines.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineProphylactic vaccinemRNA vaccineRecombinant protein (for VLP vaccines)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Oramed Pharmaceuticals/Oravax Medical – partnership for oral COVID–19 VLP vaccine development using combined technologies
Beyond the preview
Go deeper on Premas Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Premas Biotech.